$5.34
3.09% yesterday
Nasdaq, Sep 04, 10:16 pm CET
ISIN
US56400P7069
Symbol
MNKD

MannKind Corporation Stock News

Neutral
GlobeNewsWire
8 days ago
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at the upcoming investor conferences. MannKind's Chief Executive Officer Michael Cast...
Neutral
GlobeNewsWire
9 days ago
DANBURY, Conn. and BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) --  MannKind Corporation (Nasdaq: MNKD) today announced that United Therapeutics Corporation (Nasdaq: UTHR) has exercised its option—granted under the companies' 2018 license and collaboration agreement—to develop a second dry powder inhalation therapy.
Neutral
Business Wire
9 days ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of scPharmaceuticals Inc. (NasdaqGS: SCPH) to MannKind Corporation (NasdaqGM: MNKD). Under the terms of the proposed transaction, shareholders of scPharmaceuticals would receive a cash payment of $5.35 per...
Neutral
Seeking Alpha
10 days ago
MannKind Corporation (NASDAQ:MNKD ) Mergers and Acquisition Conference Call August 25, 2025 8:30 AM ET Company Participants Christopher B. Prentiss - Chief Financial Officer Michael E.
Neutral
GlobeNewsWire
11 days ago
Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX ® , an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet need Upfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up...
Neutral
Seeking Alpha
29 days ago
MannKind Corporation (NASDAQ:MNKD ) Q2 2025 Earnings Call August 6, 2025 9:00 AM ET Company Participants Christopher B. Prentiss - Chief Financial Officer Michael E.
Positive
Seeking Alpha
29 days ago
Today, we take another look at MannKind Corporation, which specializes in inhaled therapeutics for endocrine and orphan lung diseases, with a market cap of $1.15 billion. The company just reported second-quarter results and continues to enjoy universal support from the analyst firm community. MannKind saw decent growth from its two core products on the market in Q2 and just signed a new non-dil...
Positive
The Motley Fool
30 days ago
MannKind (MNKD -9.52%), a biopharmaceutical firm known for its inhaled insulin and pulmonary therapeutics, released its second quarter 2025 earnings on August 6, 2025. The most significant news from this release was a 6% increase in total revenue to $76.53 million (GAAP), primarily from royalty gains and higher Afrezza inhaled insulin sales.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today